2022
DOI: 10.54029/2022aex
|View full text |Cite
|
Sign up to set email alerts
|

Eczematous skin reaction after intravenous immunoglobulin therapy in axonal Guillain-Barré syndrome

Abstract: Background: Intravenous immunoglobulin (IVIG) treatment in Guillain-Barré syndrome (GBS) is relatively easy to administer and safe due to infrequent, non-severe side effects. Adverse effects can include skin reactions, the causes of which have not been fully elucidated. In this study, we investigated skin reactions following IVIG treatment for acute inflammatory neuropathy. We examined the relationship between the clinical results in the neuropathy and the clinical profile of skin reactions. Methods: We retros… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 26 publications
0
1
0
Order By: Relevance
“…Guillain‐Barré syndrome (GBS) is an acute inflammatory peripheral neuropathy and the most common cause of acute flaccid paralysis 1–4 . It occurs within a few weeks after the occurrence of an antecedent infection in 60%–70% of cases.…”
Section: Introductionmentioning
confidence: 99%
“…Guillain‐Barré syndrome (GBS) is an acute inflammatory peripheral neuropathy and the most common cause of acute flaccid paralysis 1–4 . It occurs within a few weeks after the occurrence of an antecedent infection in 60%–70% of cases.…”
Section: Introductionmentioning
confidence: 99%